Amgen Inc. Stock News

In the latest trading session, Amgen (AMGN) closed at $286.53, marking a +0.93% move from the previous day.

Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

Amgen Inc. AMGN said Tuesday that the regulatory review of its supplemental new drug application seeking full approval of Lumakras resulted in a “complete response letter” from the U.S. Food and D

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

5 Biotech Acquisition Targets To Accumulate In 2024

Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing in b

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

The Dogs of the Dow in 2023 are up an average of just 2.8%, lagging the market by the widest amount since 2006, per Bespoke Investment Group, as quoted on Investors Business Daily. But more importantl

BMO upgraded Amgen, Inc. (NASDAQ:AMGN) to "outperform" from "market perform" earlier, and hiked its price objective to $326 from $286, implying 18.3% upside to its last close.

Shares of Amgen Inc. AMGN, +0.01% gained 1.1% premarket on Tuesday after BMO Capital Markets analysts upgraded the stock to outperform, from market perform, citing the company's “underappreciated”

Amgen is a biotech company with a strong track record of returning capital to shareholders and maintaining high profitability. The company has outperformed the S&P 500 and other pharmaceutical peers i

Amgen Inc. is a biotech company known for its innovative therapies and focus on areas with significant unmet medical needs. The company showcases strong financial health, with a past quarter of increa

Amgen (AMGN) reachead $275.48 at the closing of the latest trading day, reflecting a +0.01% change compared to its last close.

Colgate-Palmolive, Amgen, and others have solid records of increasing dividend payments.